**Name of Journal: *World Journal of Gastroenterology***

**ESPS Manuscript NO: 27944**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Study***

**Clinical features of upper gastrointestinal serrated lesions: an endoscopy database analysis of 98746 patients**

Cao HL *et al*. Clinical features of UPGI serrated lesions

**Hai-long Cao, Wen-xiao Dong, Meng-que Xu, Yu-jie Zhang, Si-nan Wang, Mei-yu Piao, Xiao-cang Cao, Bang-mao Wang**

**Hai-long Cao, Wen-xiao Dong, Meng-que Xu, Si-nan Wang, Mei-yu Piao, Xiao-cang Cao, and Bang-mao Wang,**Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University; Tianjin Institute of Digestive Disease, Tianjin 300052, China

Yu-jie Zhang, Department of Pathology, General Hospital, Tianjin Medical University, Tianjin 300052, China

**Author contributions:** Cao HL and Dong WX contributed equally to this work; Cao HL, Dong WX, Xu MQ, Zhang YJ, Wang SN and Piao MY were involved in the data collection and analysis; Cao HL, Dong WX and Xu MQ were involved in writing the manuscript; Cao HL, Zhang YJ, Piao MY, Cao XC and Wang BM were involved in the study design and the critical review of the manuscript; Cao HL and Wang BM were involved in the critical revision of the manuscript; and all authors who contributed to the design and writing of the paper agreed with the final version and the content of the manuscript.

**supported by** the National Natural Science Foundation of China, No. 81300272, No. 81470796 to Cao HL, and No. 81570478 to Wang BM.

**Institutional review board statement:** The study was reviewed and approved by the Ethics Committee of General Hospital, Tianjin Medical University.

**Informed consent statement:** Informed consent for esophagogastroduodenoscopy and colonoscopy was obtained from all of the participants before the procedure.

**Conflict of interest statement:** The authors have no conflicts of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Dr. Bang-Mao Wang,** Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Heping District 154 Anshan Road, Tianjin 300052, China. tjmughgi@hotmail.com

**Telephone:** +86-22-60362608

**Fax:** +86-22-27813550

**Received:** June 22, 2016

**Peer-review started:** June 24, 2016

**First decision:** September 20, 2016

**Revised:** November 3, 2016

**Accepted:** November 14, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To analyse the clinical features of patients with the serrated lesions in the upper gastrointestinal tract (UPGI) tract.

***Methods***

Patients who underwent routine esophagogastroduodenoscopy (EGD) at the Digestive Endoscopy Centre of General Hospital, Tianjin Medical University between January 2011 and December 2015 were consecutively recruited. Patients with UPGI serrated lesions were consecutively identified. The patients’ demographics and histopathology were recorded. The colorectal findings for patients who underwent colonoscopy simultaneously or within six months were also extracted from the colonoscopy database. In addition, we analysed differences in colorectal neoplasia detection between the study patients and randomly selected patients matched for age and gender who did not exhibit serrated lesions and who also underwent colonoscopy in the same period.

***Results***

A total of 21 patients out of 98746 patients (0.02%) who underwent EGD were confirmed to have serrated lesions with predominantly crenated, sawtooth-like configurations. The mean age of the 21 patients was (55.3 ± 17.2) years, and 11 patients were male (52.4%). In terms of the locations of the serrated lesions, 17 were found in the stomach (including 3 in the cardia, 9 in the corpus and 5 in the antrum), 3 were found in the duodenum, and 1 was found in the esophagus. Serrated lesions were found in different mucosal lesions, with 14 lesions were detected in polyps (8 hyperplastic polyps and 6 serrated adenomas with low grade dysplasia), 3 detected in Ménétrier gastropathy, 3 detected in an area of inflammation or ulcer, and 1 detected in the intramucosal carcinoma of the duodenum. In addition, colonoscopy data were available for 18 patients, and a significantly higher colorectal adenoma detection rate was observed in the UPGI serrated lesions group than in the randomly selected age- and gender-matched group without serrated lesions who also underwent colonoscopy in the same period (38.9% *vs* 11.1%, OR = 5.091, 95%CI: 1.534-16.890, *P* = 0.010). The detection rate of advanced adenoma was also higher in the UPGI serrated lesions group (22.2% *vs* 4.2%, OR = 6.571, 95%CI: 1.322-32.660, *P* = 0.028).

***Conclusion***

Serrated lesions in the UPGI were detected in various mucosal lesions with different pathological morphologies. Moreover colonoscopy is recommended for the detection of concurrent colorectal adenoma for these patients.

**Key words:** Clinical features; Upper gastrointestinal tract; Serrated lesions; Colorectal adenoma; Colorectal cancer

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In this retrospective study, the clinical features of the serrated lesions in the upper gastrointestinal tract (UPGI) were analysed. We found that serrated lesions in the UPGI occurred can be found in different mucosal lesions. Furthermore, a significantly higher colorectal adenoma detection rate was observed in the UPGI serrated lesions group than in the randomly selected age- and gender-matched group from our colonoscopy database, and the detection rate of advanced adenoma was also higher in the UPGI serrated group. Therefore, colonoscopy is recommended for the detection of concurrent colorectal adenoma in patients with UPGI serrated lesions.

Cao HL, Dong WX, Xu MQ, Zhang YJ, Wang SN, Piao MY, Cao XC, and Wang BM. Clinical features of upper gastrointestinal serrated lesions: an endoscopy database analysis of 98746 patients. *World J Gastroenterol* 2016; In press

**INTRODUCtION**

A new “alternative” pathway by which adenocarcinomas develop from serrated lesions was recently described by *Jass and Smith*, and it may account for 10% to 30% of all cases of colorectal cancer (CRC)[[1-5](#_ENREF_1)]. According to the 2010 WHO classification, three subgroups including hyperplastic polyps (HP), traditional serrated adenoma (TSA), and sessile serrated adenoma/polyp have been divided, forming a heterogeneous group of colorectal lesions. However, detailed information about patients with serrated lesions in the upper gastrointestinal tract (UPGI) is very limited.

UPGI nonconventional adenomatous and nonadenomatous types of dysplasia, such as serrated adenoma and dysplasia, have recently been identified. In 1992, Stolte *et al*[[6](#_ENREF_6)]revealed a characteristic “hypertrophy” of the parietal cells that was induced by omeprazole, and produced a serrated internal gland profile. In addition, in 2001, Rubio[[7](#_ENREF_7)]reported the first case of serrated adenoma of the stomach. Since then, serrated dysplasia has been reported in patients with Ménétrier-like lymphocytic gastritis[[8](#_ENREF_8)], reactive gastropathy[[9](#_ENREF_9)] and even Barrett’s esophagus[[10](#_ENREF_10)], and it is epitomised by hypereosinophilic cytoplasm, small oval-shaped nuclei and prominent luminal serration. Serrated adenomas characterized by branched villi exhibiting lateral saw-tooth indentations lined with dysplastic cells or “Christmas-tree-like” serrated configurations have also been detected in the esophagus[[11](#_ENREF_11)], the stomach[[12-20](#_ENREF_12)], the duodenum[[19](#_ENREF_19),[21-27](#_ENREF_21)], the pancreas[[28](#_ENREF_28)] and the gallbladder[[29](#_ENREF_29)]. Although serrated adenomas are rare, recent reports indicate that 53.4% (39/73) of traditional serrated adenomas in the UPGI are invasive carcinomas[[30](#_ENREF_30)]. Therefore, analysing the comprehensive clinical features of UPGI serrated lesions is still worthwhile.

Moreover, a meta-analysis was recently performed to assess patients at risk of developing colorectal polyps with upper digestive polyps, and the finding showed that the incidence of colorectal neoplasia was markedly higher in patients with UPGI polyps than in those without UPGI polyps[[31](#_ENREF_31)]. However the relationship between UPGI serrated lesions and colorectal neoplasia is not clear. Hence, in the present study, we analysed the clinical and pathological features of serrated lesions in the UPGI and also evaluated the colonoscopy findings in the study group.

**Materials and methods**

***Design and patients***

Patients who underwent a routine esophagogastroduodenoscopy (EGD) at the Digestive Endoscopy Centre of the General Hospital, Tianjin Medical University between January 2011 and December 2015 were consecutively recruited. Patients who underwent other types examinations, such as therapeutic endoscopy and emergent endoscopy, were not included. The patients’ features, including their age, gender, body mass index (BMI), endoscopy indications, family history of cancer and the size and location of the lesions were extracted from the endoscopy reports and patient questionaires.

In patients with histologically confirmed UPGI serrated lesions, colonoscopy was required simultaneously or within six months. Each patient was compared to 4 randomly selected age- and gender-matched controls without serrated lesions who also underwent a colonoscopy within the same time period. We also analysed the differences in colorectal neoplasia detection in each study patient and in the control group. Patients with a history of colonoscopy polypectomy or surgical resection of the colon or rectum and patients with a family history of CRC, polyposis syndromes or inflammatory bowel disease were excluded. Informed consents for EGD and colonoscopy were obtained from all of the participants before the procedure, and the researchers had access to the patients’ identifying information. The study was approved by the Ethics Committee of the General Hospital, Tianjin Medical University.

***Endoscopic procedure***

Before undergoing the EGD, all of the patients were asked to undergo a fasting period of at least 12 h and water deprivation for 8 h. Polyethylene glycol lavage was prescribed for bowel preparation and watery diarrhea excretion prior to the procedure indicated adequate intestinal preparation for the colonoscopy. Experienced endoscopists carefully performed the colonoscopies while the patients were under anaesthesia. The cardiopulmonary function was monitored by an anaesthetist, and the patients were maintained under general anaesthesia with intravenous injections of propofol. Electronic gastroscopy (GIF-Q260, Olympus, Tokyo, Japan) and colonoscopy (Olympus CF-Q260, Olympus, Tokyo, Japan) equipment were used for all procedures.

***Pathological*** ***evaluation***

All of the biopsy specimens or resected lesions that collected during the EGD were fixed in 10% formalin within 1 h of removal and then fixed for a minimum of 4h. All haematoxylin and eosin-stained sections used for the pathological assessment and classification were evaluated by experienced pathologists. Serrated lesions in the UPGI exhibit clinically and molecularly diverse changes with common features, such as crypt luminal morphology characterized by glandular serration. In addition, advanced colorectal adenomas (AA) were defined as tubular adenomas > 10 mm in size, adenomas with villous histology, or high grade dysplasia. Multiple polyps were categorized according to the most advanced lesion.

***Statistical analysis***

All of the statistical analyses were performed with SPSS 17.0 (Chicago, IL, United States) for Windows. The means and standard deviations (SDs) were calculated for continuous variables. Categorical or constitute data were expressed as percentage. Risks of colorectal neoplasia between patients with serrated lesions in the UPGI and the control group in our database were compared *via* the χ2 testor Fisher’s exact test. The level of statistically significance was set at two-tailed *P* < 0.05.

**Results**

***General information on the study group***

During the study period, 98746 routine EGDs were performed. A total of 21 patients with serrated lesions that exhibited predominantly crenated, sawtooth-like configurations were diagnosed. The mean age of these 21 patients with serrated lesions was (55.3 ± 17.2) years, and the proportion of males was 52.4% (11/21). The mean BMI of the patients was (24.9 ± 5.8) kg/m2 and 13 patients (61.9%) had a BMI within the normal range. The proportions of patients with a history of smoking, alcohol use, and a family history of gastric cancer were 33.3% (7/21), 47.6% (10/21) and 4.8% (1/21), respectively. The indications for EGD included upper abdominal pain (23.8%, 5/21), nausea, vomiting and reflux (19.0%, 4/21), anemia and edema (19.0%, 4/21), positive fecal occult blood test (14.3%,3/21), a history of gastric polyps (14.3%, 3/21) and dyspepsia (9.5%, 2/21) (Table 1).

***Distribution of serrated lesions detected in UPGI***

Table 2presents the distribution of serrated lesions: 17 lesions were detected in the stomach (including 3 in the cardia, 9 in the corpus and 5 in the antrum), 3 were detected in the duodenum (2 in the duodenal bulb and 1 in the descending part) and 1 was detected in the lower esophagus.

***Morphology of UPGI serrated lesions***

The mean size of the UPGI serrated lesions was (11.7 ± 10.3) mm. The diameter was less than 20 mm in 18 patients, and more than 30 mm in 2 patients. The histopathological features of different serrated lesions were divided into four morphologies: (1) serrated hyperplasia (6/21) which was detected in areas of inflammation or ulcer lesions (3/21) and Ménétrier gastropathy (3/21); (2) HPs (8/21); (3) serrated adenoma with low grade dysplasia (6/21); and (4) Serrated lesion (1/21), which was found in the intramucosal carcinoma of the duodenum. The typical pathological images and clinical features are shown in Figure 1 and Table 2.

***Prevalence of colorectal neoplasia in patients with UPGI serrated lesions***

A total of 18 patients with UPGI serrated lesions (81.7%, 18/21) underwent a colonoscopy simultaneously or within six months, and 3 patients refused to undergo a colonoscopy. We then evaluated the colonoscopy findings of these patients. Three non-advanced colorectal adenomas (NAA) and 4 AAs (1 tubular adenoma with high grade dysplasia, 2 tubulovillous adenomas and 1 adenoma > 10 mm in size) were found, and all of these colorectal adenomas were detected only in patients with UPGI serrated adenomas or polyps. The remaining colonoscopy reports included 7 colorectal HPs and 4 patients without polyps. CRC was not detected found in 18 patients. The colonoscopy findings in the patients with UPGI serrated lesions are illustrated in Table 3. We also compared the detection rate of colorectal adenoma in the UPGI serrated lesions group with that in the control group in our colonoscopy database(Table 4). A total of 72 age- and gender-matched patients without serrated lesions who had presented to our centre for EGD and colonoscopy were randomly selected as the control group. A significantly higher colorectal adenoma detection rate was observed in the UPGI serrated lesions group than in the control group (38.9% *vs* 11.1%,OR = 5.091; 95%CI: 1.534-16.890; *P* = 0.010), and a higher detection rate of advanced adenoma was observed in the UPGI serrated lesions group (22.2% *vs* 4.2%, OR = 6.571; 95%CI: 1.322-32.660; *P* = 0.028).

**Discussion**

Since 1990, serrated polyps have been commonly found during colonoscopy and recognized as an important process in the development of CRC[[1](#_ENREF_1),[32](#_ENREF_32),[33](#_ENREF_33)]. Limited reports focused on the clinical features of UPGI serrated lesions because of the low prevalence of these lesions, and few articles have described serrated adenomas in the UPGI[7-25]. Thus, serrated polyps have not been previously listed in the classifications of the upper digestive tract[[34-36](#_ENREF_34)]. The present study provides current information on serrated lesions in different UPGI diseases, including inflammation or ulcer, Ménétrier gastropathy, HPs, serrated adenomas, and adenocarcinoma, as well as the serrated profile found in cases of reactive gastropathy[[8](#_ENREF_8),[9](#_ENREF_9)]. We also found that nearly half of the UPGI serrated lesions were located in the gastric corpus, and 2/3 of the lesions were detected in polyps in the current study. In addition, we evaluated the colonoscopy findings of patients with UPGI serrated lesions, and found a significantly higher colorectal adenoma detection rate in the serrated lesions group than in the control group, thus colonoscopy may be recommended to exclude the presence of concurrent colorectal adenomas in these patients.

This study provides the first description the detection and distribution of serrated lesions in the UPGI, and analysed the colonoscopy results of these patients compared with the control group. Simple and readily accepted methods (EGD and colonoscopy) were used, and the possibility of clinical heterogeneity was minimized because of the study setting, which was within a tertiary endoscopic centre. However, several limitations should be mentioned. First, relatively small sample size was used in the present study because of the rarity of serrated lesions, and a statistical analysis of the age, gender, BMI and family history of patients with different mucosal lesions couldnot be conducted. Second, this study was conducted in a tertiary endoscopic centre, therefore selection bias likely occurred. In addition, more rigorous studies with larger sample sizes from multiple clinical centres are necessary to determine whether patients with UPGI serrated lesions have a higher rate of colorectal adenomas and to ascertain whether these findings similar to those in previous reports[[31](#_ENREF_31),[37](#_ENREF_37)].

Activating mutations of the RAS-RAF-MAPK pathway have been reported to initiate and sustain lesions in the serrated pathway, and the presence of a positive CpG island methylation phenotype and DNA repair genes might play a major role in colorectal neoplastic progression[[5](#_ENREF_5),[38](#_ENREF_38),[39](#_ENREF_39)]. Compared with serrated polyps of the colon, extracolonic serrated polyps are virtually undescribed and their genetic alterations are largely unknown. The pathological findings and analysis of the molecular alterations of 13 serrated neoplasms of the small intestine indicated that almost half of the neoplasms demonstrated high-grade dysplasia or were associated with an adenocarcinoma. However, the absence of the *BRAF*V600E mutation does not support a role for the serrated neoplasia pathway in the development of these lesions, as it does in colorectal serrated polyps[[26](#_ENREF_26)]. Another report confirmed that oncogenic *KRAS* mutation was the most common abnormality in extracolonic serrated polyps, whereas a microsatellite instability and a CpG island methylator phenotype were less commonly[[19](#_ENREF_19)]. Rubio *et al*[[30](#_ENREF_30)]presented a TSA pathway of carcinogenesis in the UPGI, and 53.4% (39/73) of the UPGI TSAs reported in the literature are associated with invasive carcinomas, however, we only detected one case associated with duodenal cancer. The younger average age of the patients with serrated adenoma in our study (62.2 ± 11.4) than that in the past reports (66.4 ± 11.7) compared with that in previous may provide a suitable explanation for this phenomenon. Hence, the mechanism that causes these lesions to evolve into invasive carcinomas remains elusive.

In conclusion, serrated lesions in the UPGI, which represents a rarely described histological phenotype, were observed in various mucosal lesions with different pathological morphologies. Moreover, colonoscopy is recommended to exclude the presence of concurrent colorectal carcinomas in these patients. However, further studies are needed to clarify the clinical significance of these lesions.

**Acknowledgments**

We thank all of the doctors, nurses and pathologists who helped to manage the patients who underwent endoscopies in our centre.

**COMMENTS**

***Background***

Recently, a new “alternative” pathway by which adenocarcinomas develop from serrated lesions was first described by Jass and Smith, and this pathway may account for 10% to 30% of all cases of colorectal cancer. However, information on upper gastrointestinal (UPGI) serrated lesions is limited. UPGI nonconventional adenomatous and nonadenomatous types of dysplasia, such as serrated adenoma and dysplasia, have been recently identified. Although serrated adenomas are rare, recent reports have indicated that 53.4% (39/73) of traditional serrated adenomas in the UPGI are invasive carcinomas. Therefore, analysing the comprehensive clinical features of the UPGI serrated lesions is still worthwhile.

***Research frontiers***

Colorectal serrated polyps are recognized as important contributors to colorectal cancer. However, detailed information on upper gastrointestinal serrated lesions is limited. The results of this study contribute to the analysis of the clinical features of serrated lesions in the UPGI, and the findings recommend colonoscopy for the detection of to find concurrent colorectal adenomas in these patients.

***Innovations and breakthrough***

In this article, the authors found that serrated lesions in the UPGI occur in different mucosal lesions, such as areas of inflammation and ulcers, hyperplastic polyps, serrated adenomas and Ménétrier gastropathy. Furthermore, a significantly higher colorectal adenoma detection rate was observed in the UPGI serrated lesions group than in the randomly selected age- and gender-matched group from our colonoscopy database, and the detection rate of advanced adenoma was also higher in the UPGI serrated lesions group. Therefore, colonoscopy is recommended for the detection of concurrent colorectal adenomas in patients with UPGI serrated lesions.

***Applications***

This study shows that serrated lesions in the UPGI occur in different mucosal lesions. Furthermore, patients diagnosed with serrated lesions in the UPGI, should undergo a colonoscopy to detect any concurrent colorectal adenomas.

***Terminology***

UPGI: Endoscopic examination that includes esophagus, stomach, ampulla and the descending part of the duodenum.

***Peer-review***

Although the serrated lesions in UPGI are rare in the population, it is very important to understand its clinical and pathological features as such lesions maybe related to invasive carcinoma in UPGI exhibited. Furthermore, authors found in this study that the serrated lesions in UPGI are associated with higher colorectal adenoma detection rate.

**References**

1 **Jass JR**, Smith M. Sialic acid and epithelial differentiation in colorectal polyps and cancer--a morphological, mucin and lectin histochemical study. *Pathology* 1992; **24**: 233-242 [PMID: 1289763]

2 **Bordaçahar B**, Barret M, Terris B, Dhooge M, Dreanic J, Prat F, Coriat R, Chaussade S. Sessile serrated adenoma: from identification to resection. *Dig Liver Dis* 2015; **47**: 95-102 [PMID: 25445408 DOI: 10.1016/j.dld.2014.09.006]

3 **Burgess NG**, Tutticci NJ, Pellise M, Bourke MJ. Sessile serrated adenomas/polyps with cytologic dysplasia: a triple threat for interval cancer. *Gastrointest Endosc* 2014; **80**: 307-310 [PMID: 24890425 DOI: 10.1016/j.gie.2014.03.050]

4 **Huang CS**, Farraye FA, Yang S, O'Brien MJ. The clinical significance of serrated polyps. *Am J Gastroenterol* 2011; **106**: 229-40; quiz 241 [PMID: 21045813 DOI: 10.1038/ajg.2010.429]

5 **O'Brien MJ**, Zhao Q, Yang S. Colorectal serrated pathway cancers and precursors. *Histopathology* 2015; **66**: 49-65 [PMID: 25263173 DOI: 10.1111/his.12564]

6 **Stolte M**, Bethke B, Rühl G, Ritter M. Omeprazole-induced pseudohypertrophy of gastric parietal cells. *Z Gastroenterol* 1992; **30**: 134-138 [PMID: 1553828]

7 **Rubio CA**. Serrated neoplasia of the stomach: a new entity. *J Clin Pathol* 2001; **54**: 849-853 [PMID: 11684719]

8 **Rubio CA**, Ost A, Kato Y, Yanagisawa A, Rivera F, Hirota T. Hyperplastic foveolar gastropathies and hyperplastic foveolar gastritis. *APMIS* 1997; **105**: 784-792 [PMID: 9368593]

9 **Mino-Kenudson M**, Tomita S, Lauwers GY. Mucin expression in reactive gastropathy: an immunohistochemical analysis. *Arch Pathol Lab Med* 2007; **131**: 86-90 [PMID: 17227128 DOI: 10.1043/1543-2165(2007)131[86: MEIRGA]2.0.CO; 2]

10 **Odze RD**. What the gastroenterologist needs to know about the histology of Barrett's esophagus. *Curr Opin Gastroenterol* 2011; **27**: 389-396 [PMID: 21543978 DOI: 10.1097/MOG.0b013e328346f551]

11 **Rubio CA**, Tanaka K, Befrits R. Traditional serrated adenoma in a patient with Barrett's esophagus. *Anticancer Res* 2013; **33**: 1743-1745 [PMID: 23564826]

12 **Rubio CA**, Lagergren J. Serrated adenomas of the cardia. *Anticancer Res* 2004; **24**: 2113-2116 [PMID: 15274410]

13 **M'sakni I**, Rommani SR, Ben Kahla S, Najjar T, Ben Jilani S, Zermani R. Another case of serrated adenoma of the stomach. *J Clin Pathol* 2007; **60**: 580-581 [PMID: 17513520 DOI: 10.1136/jcp.2006.037960]

14 **Rubio CA**, Petersson F, Höög A, Jónasson JG, Nesi G, Chandanos E, Lindblad M. Further studies on serrated neoplasias of the cardia: a review and case report. *Anticancer Res* 2007; **27**: 4431-4434 [PMID: 18214056]

15 **Hasuo T**, Semba S, Satake S, Shirasaka D, Aoyama N, Yokozaki H. Superficially elevated-type serrated hyperplastic lesion of the stomach with minute adenocarcinoma. *Dig Endosc* 2009; **21**: 101-105 [PMID: 19691783 DOI: 10.1111/j.1443-1661.2009.00831.x]

16 **Köklü S**, Başar O, Akbal E, Ibiş M. Gastric serrated adenoma polyp treated with endoscopic band ligation (with video). *Surg Laparosc Endosc Percutan Tech* 2010; **20**: e204-e205 [PMID: 21150403 DOI: 10.1097/SLE.0b013e3181fd27ab]

17 **Rubio CA**, Björk J. Serrated adenoma of the stomach: Case report and literature review. *World J Gastrointest Endosc* 2013; **5**: 261-264 [PMID: 23678381 DOI: 10.4253/wjge.v5.i5.261]

18 **Kwon MJ**, Min BH, Lee SM, Park HY, Kang SY, Ha SY, Lee JH, Kim JJ, Park CK, Kim KM. Serrated adenoma of the stomach: a clinicopathologic, immunohistochemical, and molecular study of nine cases. *Histol Histopathol* 2013; **28**: 453-462 [PMID: 23404616]

19 **Taggart MW**, Rashid A, Estrella J, Abraham SC. Serrated Polyps of the Extracolonic Gastrointestinal Tract: Histologic Findings and Genetic Alterations. Laboratory Investigation 2012; **92**: 182a-182a

20 **Rubio CA**, Schmidt PT. An additional case of gastric serrated adenoma. *Anticancer Res* 2014; **34**: 3007-3010 [PMID: 24922666]

21 **Rubio CA**. Serrated adenoma of the duodenum. *J Clin Pathol* 2004; **57**: 1219-1221 [PMID: 15509689 DOI: 10.1136/jcp.2004.016360]

22 **Roche HJ**, Carr NJ, Laing H, Bateman AC. Hyperplastic polyps of the duodenum: an unusual histological finding. *J Clin Pathol* 2006; **59**: 1305-1306 [PMID: 17142571 DOI: 10.1136/jcp.2005.035022]

23 **Wagner PL**, Chen YT, Yantiss RK. Immunohistochemical and molecular features of sporadic and FAP-associated duodenal adenomas of the ampullary and nonampullary mucosa. *Am J Surg Pathol* 2008; **32**: 1388-1395 [PMID: 18670349 DOI: 10.1097/PAS.0b013e3181723679]

24 **Rosty C**, Buchanan DD, Walters RJ, Carr NJ, Bothman JW, Young JP, Brown IS. Hyperplastic polyp of the duodenum: a report of 9 cases with immunohistochemical and molecular findings. *Hum Pathol* 2011; **42**: 1953-1959 [PMID: 21733555 DOI: 10.1016/j.humpath.2011.02.018]

25 **Sarbia M**, Jüttner S, Bettstetter M, Berndt R. [Serrated polyps of the duodenum. Three cases with immunohistological and molecular pathological findings]. *Pathologe* 2013; **34**: 347-351 [PMID: 23440291 DOI: 10.1007/s00292-013-1754-5]

26 **Rosty C**, Campbell C, Clendenning M, Bettington M, Buchanan DD, Brown IS. Do serrated neoplasms of the small intestine represent a distinct entity? Pathological findings and molecular alterations in a series of 13 cases. *Histopathology* 2015; **66**: 333-342 [PMID: 24894811 DOI: 10.1111/his.12469]

27 **Iwamuro M**, Hori K, Tanaka T, Okada H. Serrated polyp of the duodenum. *Gastrointest Endosc* 2015; **82**: 966-97; discussion 967 [PMID: 26112676 DOI: 10.1016/j.gie.2015.05.021]

28 **Rubio CA**, Grimelius L, Von Sivers K, Höög A. Intraductal serrated adenoma of the pancreas. A case report. *Anticancer Res* 2005; **25**: 3099-3102 [PMID: 16080572]

29 **Rubio CA**. Serrated adenoma of the gallbladder: a case report. *Anticancer Res* 2015; **35**: 3485-3487 [PMID: 26026114]

30 **Rubio CA**. Traditional serrated adenomas of the upper digestive tract. *J Clin Pathol* 2016; **69**: 1-5 [PMID: 26468393 DOI: 10.1136/jclinpath-2015-203258]

31 **Wu ZJ**, Lin Y, Xiao J, Wu LC, Liu JG. Clinical significance of colonoscopy in patients with upper gastrointestinal polyps and neoplasms: a meta-analysis. *PLoS One* 2014; **9**: e91810 [PMID: 24637723 DOI: 10.1371/journal.pone.0091810]

32 **Yang S**, Farraye FA, Mack C, Posnik O, O'Brien MJ. BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. *Am J Surg Pathol* 2004; **28**: 1452-1459 [PMID: 15489648]

33 **Szylberg Ł**, Janiczek M, Popiel A, Marszałek A. Serrated polyps and their alternative pathway to the colorectal cancer: a systematic review. *Gastroenterol Res Pract* 2015; **2015**: 573814 [PMID: 25945086 DOI: 10.1155/2015/573814]

34 **Cao H**, Wang B, Zhang Z, Zhang H, Qu R. Distribution trends of gastric polyps: an endoscopy database analysis of 24 121 northern Chinese patients. *J Gastroenterol Hepatol* 2012; **27**: 1175-1180 [PMID: 22414211 DOI: 10.1111/j.1440-1746.2012.07116.x]

35 **Goldstein NS**, Lewin KJ. Gastric epithelial dysplasia and adenoma: historical review and histological criteria for grading. *Hum Pathol* 1997; **28**: 127-133 [PMID: 9023391]

36 **Appelman HD**. Pathology of the esophagus, stomach, and duodenum. Contemporary issues in surgical pathology. New York: Churchill Livingstone. ix, 1984: 296

37 **Cao H**, He N, Song S, Xu M, Piao M, Yan F, Wang B. Is surveillance colonoscopy necessary for patients with sporadic gastric hyperplastic polyps? *PLoS One* 2015; **10**: e0122996 [PMID: 25874940 DOI: 10.1371/journal.pone.0122996]

38 **Inoue A**, Okamoto K, Fujino Y, Nakagawa T, Muguruma N, Sannomiya K, Mitsui Y, Takaoka T, Kitamura S, Miyamoto H, Okahisa T, Fujimori T, Imoto I, Takayama T. B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF), sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P. *Br J Cancer* 2015; **112**: 403-412 [PMID: 25314065 DOI: 10.1038/bjc.2014.545]

39 **Anderson JC**. Pathogenesis and management of serrated polyps: current status and future directions. *Gut Liver* 2014; **8**: 582-589 [PMID: 25368744 DOI: 10.5009/gnl14248]

**P-Reviewer:** Ahmad Z, Biondi A, Fialova A, Zhao Jb

**S-Editor:** Gong ZM **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Typical pathological images of serrated lesions in upper gastrointestinal tract.** Serrated lesions characterized by epithelial cells with luminal infolding and a serrated growth pattern were shown. A: Serrated hyperplasia in esophagitis (× 40). B: Serrated hyperplasia in the Ménétrier gastropathy: marked foveolar hyperplasia and glandular cysts with serrated lesions in the stomach (× 100). C: Hyperplastic polyp in the stomach: a serrated polyp without overt cytological atypia showed narrowed crypt bases that were predominantly lined with immature cells (× 100). D: Serrated adenoma with low grade dysplasia in the duodenum: a serrated polyp with enlarged nuclei, a pencil-shaped, hyperchromaticity and nuclear stratification (× 100).

**Table 1 General information on patients with serrated lesions in upper gastrointestinal tract**

|  |  |
| --- | --- |
|  | ***n* (%)** |
| TotalMean age (yr), mean ± SDGender, maleBody mass index (kg/m2), mean ± SD18.5-23.9≥ 24.0History of smokingAlcohol consumptionFamily history of gastric cancer Indications for endoscopy upper abdominal painnausea, vomit and refluxanemia and edemapositive fecal occult blood test a history of gastric polypsdyspepsia | 2155.3 ± 17.211 (52.4)24.9 ± 5.813 (61.9)8 (38.1)7 (33.3)10 (47.6)1 (4.8)5 (23.8)4 (19.0)4 (19.0)3 (14.3)3 (14.3)2 (9.5) |

**Table 2 Clinical features of serrated lesions in upper gastrointestinal tract**

|  |  |
| --- | --- |
|  | ***n* (%)** |
| **Size (mm), mean ± SD**≤ 55-1010-2020-30≥ 30**Distribution**esophaguscardiacorpusantrumduodenum**Morphology**serrated hyperplasiahyperplastic polypsadenomaadenocarcinoma**Situation of serrated lesions in mucosal lesions**inflammation or ulcerserrated polypsMénétrier gastropathyduodenal cancer**Colonoscopy findings**no-polyphyperplastic polypsnon-advanced adenomasadvanced adenomastubular adenoma with high grade dysplasiatubulovillous adenomaadenoma > 10 mm | 11.7 ± 10.38 (38.1)4 (19.0)6 (28.6)1 (4.8)2 (9.5)1 (4.8)3 (14.3)9 (42.9)5 (23.8)3 (14.3)6 (28.6)8 (38.1)6 (28.6)1 (4.8)3 (14.3)14 (66.7)3 (14.3)1 (4.8)184 (22.2)7 (38.9)3 (16.7)4 (22.2)1 (5.6)2 (11.1)1 (5.6) |

**Table 3 Colonoscopy findings in the patients with serrated lesions in upper gastrointestinal tract**

|  |  |
| --- | --- |
| **Serrated lesions in upper gastrointestinal tract mucosal lesions (*n*)** | **Colonoscopy findings (*n*)** |
| inflammation or ulcer (3)HPs (8)serrated adenoma (6)Ménétrier gastropathy (3)duodenal cancer (1) | HPs (1)AA (2), NAA (1), HPs (2)AA (2), NAA (2), HPs (2)HPs (2)absent |

HPs: hyperplastic polyps; AA: advanced adenoma; NAA: non-advanced adenoma.

**Table 4 Prevalence of colorectal adenoma in patients with serrated lesions in upper gastrointestinal tract and the control group *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Patients with serrated lesions in UPGI (*n* = 18)** | **Average group****(*n* = 72)** | **OR(95%CI)** | ***P* value** |
| Colorectal adenoma  | 7 (38.9) | 8 (11.1) | 5.091 (1.534-16.890) | 0.010 |
| Non-Advanced adenoma  | 3 (16.7) | 5 (6.9) | 2.680 (0.576-12.463) | 0.195 |
| Advanced adenoma  | 4 (22.2) | 3 (4.2) | 6.571 (1.322-32.660) | 0.028 |